• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma.

作者信息

Liu Zhao-Yun, Deng Ling, Jia Yue, Liu Hui, Ding Kai, Wang Wei, Zhang Hongkai, Fu Rong

机构信息

Department of Hematology, Tianjin Medical University General Hospital, Tianjin, P. R. China.

出版信息

Clin Transl Med. 2022 Jul;12(7):e861. doi: 10.1002/ctm2.861.

DOI:10.1002/ctm2.861
PMID:35858240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9299950/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/1bd1b327ff83/CTM2-12-e861-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/b4d979512cec/CTM2-12-e861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/8134b879de78/CTM2-12-e861-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/2641caf0271e/CTM2-12-e861-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/1bd1b327ff83/CTM2-12-e861-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/b4d979512cec/CTM2-12-e861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/8134b879de78/CTM2-12-e861-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/2641caf0271e/CTM2-12-e861-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eabf/9299950/1bd1b327ff83/CTM2-12-e861-g002.jpg

相似文献

1
CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma.CD155/TIGIT信号传导在多发性骨髓瘤中骨髓间充质干细胞诱导的自然杀伤细胞耗竭的调节中起着至关重要的作用。
Clin Transl Med. 2022 Jul;12(7):e861. doi: 10.1002/ctm2.861.
2
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.HLA I类分子、NKG2D和自然细胞毒性受体调节自然杀伤细胞对多发性骨髓瘤细胞的识别。
Blood. 2005 Jan 1;105(1):251-8. doi: 10.1182/blood-2004-04-1422. Epub 2004 Aug 24.
3
Contribution of inhibitory receptor TIGIT to NK cell education.抑制性受体 TIGIT 对 NK 细胞发育的贡献。
J Autoimmun. 2017 Jul;81:1-12. doi: 10.1016/j.jaut.2017.04.001. Epub 2017 Apr 21.
4
Bone marrow-derived mesenchymal stem cells inhibit CD8 T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.骨髓间充质干细胞通过 PD-1/PD-L1 通路抑制多发性骨髓瘤中 CD8 T 细胞免疫应答。
Clin Exp Immunol. 2021 Jul;205(1):53-62. doi: 10.1111/cei.13594. Epub 2021 May 7.
5
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.自然杀伤细胞介导的骨髓瘤细胞杀伤中对DNAX辅助分子-1（DNAM-1）、自然杀伤细胞激活受体2D（NKG2D）和自然杀伤细胞p46受体（NKp46）的需求。
Cancer Res. 2007 Sep 15;67(18):8444-9. doi: 10.1158/0008-5472.CAN-06-4230.
6
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.IL15 刺激联合 TIGIT 阻断逆转黑色素瘤中 CD155 介导的 NK 细胞功能障碍。
Clin Cancer Res. 2020 Oct 15;26(20):5520-5533. doi: 10.1158/1078-0432.CCR-20-0575. Epub 2020 Jun 26.
7
Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma.多发性骨髓瘤患者自然杀伤细胞中激活受体表达模式受损。
Leukemia. 2006 Apr;20(4):732-3. doi: 10.1038/sj.leu.2404096.
8
Blocking TIGIT/CD155 signalling reverses CD8 T cell exhaustion and enhances the antitumor activity in cervical cancer.阻断 TIGIT/CD155 信号通路可逆转 CD8 T 细胞耗竭，增强宫颈癌的抗肿瘤活性。
J Transl Med. 2022 Jun 21;20(1):280. doi: 10.1186/s12967-022-03480-x.
9
CD155/TIGIT, a novel immune checkpoint in human cancers (Review).CD155/TIGIT，人类癌症中的一种新型免疫检查点（综述）。
Oncol Rep. 2021 Mar;45(3):835-845. doi: 10.3892/or.2021.7943. Epub 2021 Jan 19.
10
Artesunate-induced ATG5-related autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via interactions between CD155 and CD226/TIGIT.青蒿琥酯诱导的 ATG5 相关自噬通过 CD155 与 CD226/TIGIT 之间的相互作用增强 NK92 细胞对子宫内膜癌细胞的细胞毒性。
Int Immunopharmacol. 2021 Aug;97:107705. doi: 10.1016/j.intimp.2021.107705. Epub 2021 Apr 29.

引用本文的文献

1
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells.骨转移来源的免疫细胞中TIGIT轴及CD39/CD73嘌呤能信号通路的表达
Cancer Immunol Immunother. 2025 Apr 24;74(6):182. doi: 10.1007/s00262-025-04030-2.
2
Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword.多发性骨髓瘤患者骨髓微环境中的间充质基质细胞：一把双刃剑。
Cancer Cell Int. 2025 Mar 26;25(1):117. doi: 10.1186/s12935-025-03741-x.
3
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.

本文引用的文献

1
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.单细胞 RNA 测序揭示多发性骨髓瘤前体阶段免疫微环境受损。
Nat Cancer. 2020 May;1(5):493-506. doi: 10.1038/s43018-020-0053-3. Epub 2020 Apr 27.
2
Dynamic responses of the haematopoietic stem cell niche to diverse stresses.造血干细胞龛对多种应激的动态反应。
Nat Cell Biol. 2020 Jan;22(1):7-17. doi: 10.1038/s41556-019-0444-9. Epub 2020 Jan 6.
3
Niches for Hematopoietic Stem Cells and Their Progeny.造血干细胞及其后代的龛位。
多组学揭示多发性骨髓瘤及其前体阶段的免疫微环境改变。
Blood Cancer J. 2024 Nov 6;14(1):194. doi: 10.1038/s41408-024-01172-x.
4
Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.多发性骨髓瘤与新型免疫检查点抑制剂的免疫治疗潜力
Ther Adv Vaccines Immunother. 2024 Oct 9;12:25151355241288453. doi: 10.1177/25151355241288453. eCollection 2024.
5
Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules.间充质基质/干细胞与免疫检查点相关分子的治疗及免疫调节潜力
Biomark Res. 2024 Mar 21;12(1):35. doi: 10.1186/s40364-024-00580-2.
6
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers.骨髓基质细胞在血液系统恶性肿瘤骨髓微环境重塑中的作用。
Biomolecules. 2023 Nov 24;13(12):1701. doi: 10.3390/biom13121701.
7
Immune checkpoint inhibitors for multiple myeloma immunotherapy.用于多发性骨髓瘤免疫治疗的免疫检查点抑制剂
Exp Hematol Oncol. 2023 Nov 28;12(1):99. doi: 10.1186/s40164-023-00456-5.
8
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.癌症免疫治疗中的 TIGIT 和 PD-1/PD-L1 的双重抑制：机制和临床试验。
Mol Cancer. 2023 Jun 8;22(1):93. doi: 10.1186/s12943-023-01800-3.
9
Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.EZH2 抑制剂联合 TIGIT 单克隆抗体对多发性骨髓瘤细胞作用的研究。
Int J Mol Sci. 2023 May 11;24(10):8603. doi: 10.3390/ijms24108603.
10
Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells.NF-κB 信号在多发性骨髓瘤与间充质基质细胞相互作用中的作用。
Int J Mol Sci. 2023 Jan 17;24(3):1823. doi: 10.3390/ijms24031823.
Immunity. 2018 Apr 17;48(4):632-648. doi: 10.1016/j.immuni.2018.03.024.
4
Targeting the bone marrow microenvironment in multiple myeloma.靶向多发性骨髓瘤中的骨髓微环境。
Immunol Rev. 2015 Jan;263(1):160-72. doi: 10.1111/imr.12233.
5
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.骨髓成纤维细胞在患者和小鼠中平行于多发性骨髓瘤的进展：体外和体内研究。
Leukemia. 2014 Apr;28(4):904-16. doi: 10.1038/leu.2013.254. Epub 2013 Sep 2.
6
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity.TIGIT与PVR和PVRL2的相互作用会抑制人类自然杀伤细胞的细胞毒性。
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63. doi: 10.1073/pnas.0903474106. Epub 2009 Oct 7.
7
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells.表面蛋白TIGIT通过促进成熟免疫调节性树突状细胞的生成来抑制T细胞活化。
Nat Immunol. 2009 Jan;10(1):48-57. doi: 10.1038/ni.1674. Epub 2008 Nov 16.
8
Functions of natural killer cells.自然杀伤细胞的功能。
Nat Immunol. 2008 May;9(5):503-10. doi: 10.1038/ni1582.
9
Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation.间充质干细胞与自然杀伤细胞的相互作用：有证据表明活化的自然杀伤细胞能够杀伤间充质干细胞，而间充质干细胞可抑制白细胞介素-2诱导的自然杀伤细胞增殖。
Blood. 2006 Feb 15;107(4):1484-90. doi: 10.1182/blood-2005-07-2775. Epub 2005 Oct 20.
10
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.HLA I类分子、NKG2D和自然细胞毒性受体调节自然杀伤细胞对多发性骨髓瘤细胞的识别。
Blood. 2005 Jan 1;105(1):251-8. doi: 10.1182/blood-2004-04-1422. Epub 2004 Aug 24.